Examination of time-kill curves of antibiotic-exposed bacteria using in vitro dynamic models allows pharmacokinetically related comparisons of antimicrobial effects but may or may not directly reflect the selective enrichment of resistant mutants. Bacterial resistance has been studied infrequently using these models. Limited observations reported from earlier timekill studies (3, 8, 21-23) precluded delineation of relationships of the area under the concentration-time curve (AUC)/MIC ratio with resistance because the ranges of the simulated AUCto-MIC ratios were too narrow. In fact, the first attempts to relate resistance to the AUC/MIC or peak concentration (C max )/MIC ratio were reported quite recently from studies that declared resistance analysis as a primary goal (1, 7, 17, 18, 20, (25) (26) (27) 30, 33, 34; A. MacGowan and K. Bowker, Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother., poster A-440, 2001). Despite wide ranges of AUC/MIC ratios simulated in some recent studies (17) (18) (19) (20) 27, 33; MacGowan and Bowker, 41st ICAAC), reasonable relationships with resistance were not established. The relatively few studies of these relationships can be classified as those that directly attempt to relate resistance to the simulated pharmacokinetics but do not (17, 20) and those that imply the existence of relationships with the AUC/MIC ratio measured within a 24-h dosing interval (AUC 24 /MIC) or with the C max /MIC ratio but do not actually report them (26, 27, 30) . One study did report a complex effect of AUC 24 /MIC and duration of moxifloxacin treatment on bacterial resistance (MacGowan and Bowker, 41st ICAAC), but the three-dimensional plots masked rather than highlighted these links. For example, according to an analysis of these data (A. Firsov, S. Vostrov, I. Lubenko, S. Zinner, and Y. Portnoy, Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-1210Chemother., abstr. A- , p. 10, 2002, the reported 72-h area under the population analysis profile-time curve as an index of pneumococcal resistance did not correlate with simulated AUC 24 /MIC ratios (r 2 , 0.04).
Examination of time-kill curves of antibiotic-exposed bacteria using in vitro dynamic models allows pharmacokinetically related comparisons of antimicrobial effects but may or may not directly reflect the selective enrichment of resistant mutants. Bacterial resistance has been studied infrequently using these models. Limited observations reported from earlier timekill studies (3, 8, (21) (22) (23) precluded delineation of relationships of the area under the concentration-time curve (AUC)/MIC ratio with resistance because the ranges of the simulated AUCto-MIC ratios were too narrow. In fact, the first attempts to relate resistance to the AUC/MIC or peak concentration (C max )/MIC ratio were reported quite recently from studies that declared resistance analysis as a primary goal (1, 7, 17, 18, 20, 25-27, 30, 33, 34; A. MacGowan and K. Bowker, Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother., poster A-440, 2001 ). Despite wide ranges of AUC/MIC ratios simulated in some recent studies (17-20, 27, 33 ; MacGowan and Bowker, 41st ICAAC), reasonable relationships with resistance were not established. The relatively few studies of these relationships can be classified as those that directly attempt to relate resistance to the simulated pharmacokinetics but do not (17, 20) and those that imply the existence of relationships with the AUC/MIC ratio measured within a 24-h dosing interval (AUC 24 /MIC) or with the C max /MIC ratio but do not actually report them (26, 27, 30) . One study did report a complex effect of AUC 24 /MIC and duration of moxifloxacin treatment on bacterial resistance (MacGowan and Bowker, 41st ICAAC), but the three-dimensional plots masked rather than highlighted these links. For example, according to an analysis of these data (A. Firsov, S. Vostrov, I. Lubenko, S. Zinner, and Y. Portnoy, Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-1210, p. 10, 2002) , the reported 72-h area under the population analysis profile-time curve as an index of pneumococcal resistance did not correlate with simulated AUC 24 /MIC ratios (r 2 , 0.04). Without AUC/MIC and C max /MIC relationships to resis-tance, reports of AUC/MIC and C max /MIC values that protect against the selection of resistant mutants appear to be contradictory. For example, with Streptococcus pneumoniae, "protective" AUC/MIC values for grepafloxacin varied from 32 h (17) to 80 h (7, 34) and those for levofloxacin varied from 9 h (17) to 26 h (20) and 50 h (34) . Furthermore, although moxifloxacin-resistant S. pneumoniae was not found at the AUC/MIC values of 107 h (7) and 250 h (34), significant losses in susceptibility were seen at AUC/MIC values as high as 43,500 h (17) .
There are many possible reasons for these contradictions. One is that simulated concentrations might or might not fall into the mutant selection window (MSW), i.e., the concentration range between the MIC and the mutant prevention concentration (MPC), within which it is proposed that resistant mutants are selected (35) . To test the MSW hypothesis and to highlight the reasons for these contradictions, the abilities of moxifloxacin, gatifloxacin, levofloxacin, and ciprofloxacin to selectively enrich resistant mutants of Staphylococcus aureus and the dynamics of antistaphylococcal effects were studied using in vitro simulations of the four fluoroquinolones at concentrations equal to the MIC, between the MIC and the MPC, and above the MPC.
(This study was presented in part at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., 27 to 30 September 2002.)
MATERIALS AND METHODS
Antimicrobial agents, bacterial strain, and susceptibility testing. Moxifloxacin and ciprofloxacin powders were kindly provided by Bayer Corporation (West Haven, Conn.), gatifloxacin was provided by Bristol-Myers Squibb (New Brunswick, N.J.), and levofloxacin was provided by Ortho-McNeill Pharmaceuticals (Raritan, N.J.). A clinical isolate of methicillin-resistant S. aureus 201 was selected for the study. MICs were determined prior to, during, and after a 3-day course of treatment with the quinolones. Susceptibility testing was performed in triplicate by broth microdilution techniques at 24 h postexposure with the organism grown in Ca 2ϩ -and Mg 2ϩ -supplemented Mueller-Hinton broth (MHB) at an inoculum size of 10 6 CFU/ml. In order to obtain more-precise values, MICs were determined by using doubling dilutions with starting concentrations of 3, 4, and 5 mg/liter as described previously (16) . MICs for S. aureus 201 were 0.09 g of moxifloxacin/ml, 0.3 g of gatifloxacin/ml, 0.6 g of levofloxacin/ml, and 0.8 g of ciprofloxacin/ml. MPCs were determined as described elsewhere (35) . Briefly, the tested microorganisms were cultured in MHB and incubated for 24 h. Then the suspension was centrifuged (at 4,000 ϫ g for 10 min) and resuspended in MHB to yield a concentration of 10 10 CFU/ml. A series of agar plates containing known fluoroquinolone concentrations was then inoculated with ϳ10 10 CFU of S. aureus. The inoculated plates were incubated for 48 h at 37°C and screened visually for growth. To estimate the MPC, logarithms of bacterial numbers were plotted against fluoroquinolone concentrations (Fig. 1) . The MPC was taken as the point where the plot intersected the x axis, i.e., the lowest fluoroquinolone concentration that completely inhibited growth. The MPCs of moxifloxacin, gatifloxacin, levofloxacin, and ciprofloxacin were estimated as 0.34, 1.17, 1.75, and 2.83 g/ml, respectively.
Simulated pharmacokinetic profiles. A series of monoexponential profiles that mimic once-daily administration of moxifloxacin, gatifloxacin, and levofloxacin and twice-daily dosing of ciprofloxacin were simulated with half-lives (t 1/2 ) of 12 h for moxifloxacin, 7 h for gatifloxacin, 6. In vitro dynamic model. A previously described dynamic model (13) was used in the study. Briefly, the model consisted of two connected flasks, one containing fresh MHB and the other with a magnetic stirrer, the central unit, containing the same broth with either a bacterial culture alone (control growth experiments) or a bacterial culture plus an antimicrobial agent (killing-regrowth experiments). Peristaltic pumps circulated fresh nutrient medium to the flasks and from the central 60-ml unit at a flow rate of 3.5 ml/h for moxifloxacin, 6 ml/h for gatifloxacin, 6.1 ml/h for levofloxacin, and 10.4 ml/h for ciprofloxacin. The clearance provided by these flow rates plus the volume of the central unit ensured monoexponential elimination of the fluoroquinolones and bacteria from the system at an elimination rate constant of 0.06 h Ϫ1 for moxifloxacin, 0.1 h Ϫ1 for gatifloxacin and levofloxacin, and 0.17 h Ϫ1 for ciprofloxacin. The system was filled with sterile MHB and placed in an incubator at 37°C. The central unit was inoculated with an 18-h culture of S. aureus. After a 2-h incubation of the bacteria, the resulting exponentially growing cultures reached approximately 10 8 CFU/ml (6 ϫ 10 9 CFU per 60-ml central compartment), and moxifloxacin, gatifloxacin, levofloxacin, or ciprofloxacin was injected into the central unit. All experiments were performed in duplicate within a 2-week interval. The reliability of fluoroquinolone pharmacokinetic simulations and the high reproducibility of the time-kill curves provided by the model have been reported elsewhere (11) .
Study design. To establish the optimal duration of treatment, i.e., the minimal course of fluoroquinolone administration that provides stable increases in the MIC, a pilot study was performed with two fluoroquinolones. Daily dosing of moxifloxacin and levofloxacin was simulated for 5 consecutive days by using 50 h as a target AUC 24 /MIC value. This value corresponds to fluoroquinolone concentrations falling into the MSW (the peak level is close to the MPC, and the trough level is close to the MIC), where resistance is expected to develop most readily (35) .
In the main study, 3-day courses of fluoroquinolone administration were simulated over a 16-fold range of the AUC 24 /MIC ratio. Daily doses of each fluoroquinolone were designed to correspond to comparable mean AUC 24 /MIC values (averages of the values reached during the 1st, 2nd, and 3rd days) ranging from 13 to 17 h to 201 to 244 h, and the times when fluoroquinolone concentrations were inside the MSW (T MSW ) ranged from Ͻ20% of the dosing interval to 40 to 90% and then back to Ͻ20% (Fig. 2) . In turn, the simulated AUC 24 /MIC values corresponded to fluoroquinolone peak concentrations close to or 2 to 3, 4 to 6, 8 to 12, or 16 to 24 times greater than the respective MICs and trough concentrations close to or 1.5, 3, 6, 12.5, or 25 times less than the MPCs.
Quantitation of the antimicrobial effect and susceptibility changes. In each experiment, multiple sampling of bacterium-containing medium from the central compartment was performed throughout the observation period. One hundredmicroliter samples were serially diluted as appropriate, and 100 l was plated onto agar plates. The duration of the experiments was defined in each case as the time until antibiotic-exposed bacteria after the last dose reached the maximum numbers observed in the absence of antibiotic (Ն10 9 CFU/ml). The lower limit of accurate detection was 2 ϫ 10 2 CFU/ml. Based on time-kill data obtained in the main study, the intensity of the antimicrobial effect (I E , defined as the area between the control growth and time-kill curves [9, 13] ) was determined from time zero to the time when the effect could no longer be detected, i.e., the time after the last fluoroquinolone dose at which the number of antibiotic-exposed bacteria reached 10 9 CFU/ml. The upper limit of bacterial numbers, i.e., the cutoff level on the regrowth and control growth curves used to determine I E , was 10 9 CFU/ml. The computation of I E at comparable AUC 24 /MIC values simulated with each drug is depicted graphically in Fig. 3 .
To reveal possible changes in susceptibility during treatment, precise fluoroquinolone MICs of bacterial cultures sampled from the model were determined daily for 6 days in the pilot study and for 4 days in the main study. The stability of resistance observed in the pilot study was determined by consecutive passaging of S. aureus that was exposed to three, four, and five doses of moxifloxacin and levofloxacin onto antibiotic-free agar plates for 10 consecutive days. MICs were determined on days 1, 3, 7, and 10 as described above.
Relationships of the emergence of resistance to the AUC 24 /MIC ratio and T MSW . To combine the data obtained with all four fluoroquinolones, increases in the MIC observed at 72 h (MIC 72 ) were related to the respective initial MIC (MIC 0 ). The ratios of MIC 72 to MIC 0 were fitted to the log AUC 24 /MIC by using a Gaussian type function where Y is the MIC 72 /MIC 0 ratio, x is log AUC 24 /MIC, x c is the log AUC 24 /MIC that corresponds to the maximal value of MIC 72 /MIC 0 , and a and b are parameters:
Equation 1 also was used to fit the MIC 24 /MIC 0 ratios of levofloxacin and trovafloxacin reported in a study with Bacteroides fragilis (25) against simulated AUC 24 /MIC ratios.
To visualize the sigmoid shape of the T MSW relationship to resistance, the MIC 72 /MIC 0 ratios were fitted to the T MSW by using the Boltzmann function
where Y is the MIC 72 /MIC 0 ratio and Y max is its maximal value, x is T MSW , x 0 is the T MSW that corresponds to Y max /2, and dx is the width parameter. Fluoroquinolone doses that prevent the selection of resistant mutants were calculated from AUC 24 /MIC ratios at which no increases in MIC occurred by using dose-AUC relationships reported earlier (10, 31) .
Relationships of the antimicrobial effect to the AUC 24 /MIC ratio. The I E was related to log AUC 24 /MIC. With each fluoroquinolone, the I E versus log AUC 24 / MIC data were fitted by the logistic function
where x is log AUC 24 /MIC, Y is I E , Y max is the maximal value of I E , and a and b are parameters reflecting the slope and amplitude of the curve whose ratio, b/a, corresponds to x 50 , i.e., to the log AUC 24 /MIC ratio that provides the antimicrobial effect equal to Y max /2.
RESULTS
Validation of the optimal study design. To establish the minimal duration of fluoroquinolone treatment that allows detection of S. aureus resistance, daily measurement of the MICs of moxifloxacin and levofloxacin was performed during the 5-day courses at AUC 24 /MIC values of approximately 60 h, which correspond to fluoroquinolone concentrations almost entirely within the MSW (Fig. 4) . As seen in Fig. 4 , significant increases in the MIC were found with both drugs beginning from the third dose. These increases were even more pronounced after the fourth dose and, especially, after the fifth dose. Serial passages of resistant isolates sampled 72, 96, and 120 to 125 h after fluoroquinolone exposure and placed on antibiotic-free plates revealed minimal or no changes in the elevated MICs, showing stable resistance after the 3rd, 7th, and (Table 1) . For example, after the 7th to 10th passage, the elevated MIC observed in the 3-day treatment with moxifloxacin was still twofold greater than the initial value. Even more stable resistance was documented in the 4-and 5-day treatments with both fluoroquinolones. The reduced susceptibility of S. aureus resulted in a gradual increase in the minimal numbers of surviving organisms (for both fluoroquinolones) that was concomitant with a slight increase in maximal bacterial counts (for levofloxacin only) (Fig. 4 ). This pilot study shows that the relatively small but stable increases in MIC observed after the third doses of moxifloxacin and levofloxacin are predictive of more-pronounced changes in the susceptibility of S. aureus after 4-and 5-day fluoroquinolone exposures. Therefore, the shorter 3-day treatments were simulated in the main study.
Emergence of resistance. Results of repeated susceptibility testing in 3-day exposures with the four fluoroquinolones are summarized in Fig. 5 . Most of the largest increases in MIC were observed after the third dose at those AUC 24 /MIC values (from 24 to 31 h to 48 to 62 h) that correspond to fluoroquinolone concentrations falling into the MSW over most of the dosing interval (T MSW , 50 to 90% of the dosing interval). Less-pronounced but significant increases in MIC occurred at AUC 24 /MIC values (97 to 123 h) corresponding to fluoroquinolone concentrations that partly overlap the MIC-MPC range (T MSW , 40 to 50% of the dosing interval). Less noticeable increases in MIC were associated with the lowest simulated AUC 24 /MIC values (15 to 16 h), with C max s exceeding the MICs of gatifloxacin and ciprofloxacin (T MSW , Յ20% of the dosing interval (see Fig. 2 ). No such increases were observed with the lowest AUC 24 /MIC values (13 to 17 h,) with C max s close to the MICs of moxifloxacin and levofloxacin (T MSW , Ͻ20% of the dosing interval). Also, no changes in MICs were seen at the highest AUC 24 (Fig. 2) . Overall, no changes in susceptibility were seen when concentrations were so small or so large as to provide T MSW equivalent to Յ20% of the dosing interval, whereas significant increases in MIC were associated with T MSW of Ͼ20%.
These MIC changes with all four fluoroquinolones were observed at similar AUC 24 /MIC or AUC 24 /MPC values. This also applies to the minimal values of AUC 24 /MIC (201 to 244 h) and AUC 24 /MPC (60 to 69 h) that prevent the selection of resistant S. aureus mutants. However, these "protective" AUC 24 /MIC and AUC 24 /MPC values correspond to quite different daily quinolone doses (Fig. 5) (400 mg), whereas the protective doses of gatifloxacin, levofloxacin, and ciprofloxacin are 90, 120, and 540% greater than their clinical doses (400 mg, 500 mg, and twice 500 mg, respectively). Therefore, AUC 24 /MIC and AUC 24 /MPC values achieved at the usual clinical dose of moxifloxacin but not at the usual clinical dose of the other three fluoroquinolones prevent the selection of resistant S. aureus. Similar patterns of the AUC 24 /MIC-dependent changes in the susceptibility of S. aureus to moxifloxacin, levofloxacin, gatifloxacin, and ciprofloxacin allow establishment of a single relationship between increases in MIC and log AUC 24 /MIC. To normalize the increases in MIC observed at 72 h with the four fluoroquinolones, they were related to the respective initial MICs. As seen in Fig. 6 , the MIC 72 /MIC 0 -versus-log AUC 24 /MIC relationship was fitted by equation 1, with the central point at an AUC 24 /MIC of 43 h, where the loss in staphylococcal susceptibility was maximal, whereas no resistance was associated with AUC 24 /MIC values of Ն200 h. Unlike the log AUC 24 /MIC plot, the T MSW plot of the MIC 72 / MIC 0 ratio was sigmoid in shape, and it was fitted by equation 2. Moreover, regardless of the simulated AUC 24 /MIC ratio, the susceptibility of S. aureus declined when T MSW exceeded 20% of the dosing interval, whereas it did not change when T MSW was less than 20% of the dosing interval.
Pharmacodynamics. The time courses of killing and regrowth of S. aureus 201 exposed to moxifloxacin, gatifloxacin, . Regrowth occurred only after the third dose of moxifloxacin, gatifloxacin, or levofloxacin and after the sixth dose of ciprofloxacin, and it occurred later with moxifloxacin than with gatifloxacin, levofloxacin, and ciprofloxacin. These differences resulted in different shapes of the AUC 24 / MIC relationships with I E (Fig. 8) . Beginning from an AUC 24 / MIC value of Ͼ60 h (moxifloxacin versus all other fluoroquinolones) and Ͼ100 h (gatifloxacin and levofloxacin versus ciprofloxacin), the I E -log AUC 24 /MIC curves differ both in terms of the slope (a) and the maximal I E (Y max ). For example, at an AUC 24 /MIC value of 125 h, the effect of moxifloxacin was 35% greater than those of gatifloxacin and levofloxacin and 47% greater than that of ciprofloxacin. As seen in Fig. 8 , the described differences were inherent in the relatively high simulated AUC 24 /MIC ratios, whereas at the lower AUC 24 /MIC ratios no differences among the curves were detected.
DISCUSSION
Emergence of resistance. This study suggests that losses in the susceptibility of S. aureus exposed to four different quinolones occur at concentrations that fall into the MSW. The most pronounced losses occurred at AUC 24 /MIC values of 25 to 60 h, when T MSW was Ͼ20% of the dosing interval. No changes in susceptibility were associated with AUC 24 /MIC values below 15 h (minimal bacterial killing) or above 200 h (maximal killing). Although similar AUC 24 /MIC values might be considered to protect against staphylococcal resistance (201 h for levofloxacin, 222 h for moxifloxacin, 241 h for gatifloxacin, and 244 h for ciprofloxacin), these values might (moxifloxacin) or might not (other three quinolones) be achieved at their usual clinical doses.
The quinolone-independent AUC 24 /MIC relationship with resistance (as expressed by increases in MIC) was reflected by a bell-shaped curve with a maximum at the AUC 24 /MIC value of 43 h (Fig. 6 ). This curve could be transformed into a sigmoid curve by plotting the ratios of elevated MICs to the initial values, i.e., MIC 72 /MIC 0 against T MSW (Fig. 6) . The MIC 72 / MIC 0 ratio correlated with T MSW regardless of whether quinolone concentrations were above or below the MPCs. Similar curves have been reported for another strain of S. aureus exposed to gatifloxacin in a study that simulated normal and impaired quinolone elimination (Firsov et al., 42nd ICAAC) . Moreover, the Gaussian function (equation 1) also fits reported resistance data on levofloxacin-and trovafloxacin-exposed B. fragilis (25) (Fig. 9) . This leads to the assumption that the described pattern of the AUC 24 /MIC-resistance curve may be quite general. Indirectly, this impression is supported by our analysis of resistance frequencies reported in a study of S. aureus exposed to norfloxacin and ciprofloxacin (1) . As seen in Fig. 10 , these data are consistent with a bell-shaped curve, despite the use of different endpoints of resistance. The more pronounced resistance to norfloxacin at a relatively large AUC 24 /MIC value (55 h) compared to a less pronounced resistance at a small AUC 24 /MIC value (3 h) no longer seems "paradoxical." Also, the similar resistance frequencies at AUC 24 /MIC values of ciprofloxacin that vary 16-fold are quite explainable. Indeed, these data fit the simple idea that selective pressure is absent below the MIC while rare double mutations are required for growth above the MPC (35) . Given the bell-shaped pattern of the AUC 24 /MIC relationships with resistance, reported failures to correlate resistance with AUC/MIC and C max /MIC values by using linear or loglinear regression are understandable. However, these failures as well as the contradictory estimates of reported "protective" AUC/MIC and C max /MIC values might result from inadequate study design. Like traditional time-kill studies, most resistance studies exposed one strain (26, 30) or a few similarly susceptible strains (1, 7, 20, 34) to clinical quinolone doses. As a result, in these studies only one or two AUC 24 /MIC values for each quinolone could be related to the observed resistance. Moreover, the majority of the simulated AUC 24 /MIC values were high enough to completely sterilize the unit, and neither population analysis of antibiotic-exposed organisms nor repeated susceptibility testing was possible. For example, in experiments with S. pneumoniae, repeated MIC determinations could be made for only one or two of six fluoroquinolones (7, 34) . Overall, only 30 to 50% of the observations in these studies provided useful information. It is fair to say that similar problems also were inherent in more rigorously designed dose (AUC/MIC)-ranging studies (17, 18, 25, 27, 33) . For example, in studies where S. pneumoniae (17) , B. fragilis (25) , and Bacteroides thetaiotamicron (27) were exposed to wide ranges of quinolone AUC 24 /MIC values, quantitative data could be obtained in only 10 to 66% of experiments. As a result, a "correspondence" between AUC/MIC values of Յ44 h (25) and AUC/MIC values of Ͻ100 h (29) , which are associated with the selection of resistant mutants, was posited, adding further con- [7, 17, 18, 34] courses) may contribute to the controversial results. As shown in our study, resistance of S. aureus was first observed on the third to fourth day of treatment and not earlier. A similar conclusion was drawn from a recent study with S. pneumoniae and Pseudomonas aeruginosa exposed to 3-day courses of moxifloxacin (A. MacGowan, and K. Bowker, 41st ICAAC): the longer the treatment, the greater the resistance. This unequivocal conclusion was possible due to the use of a novel index of resistance, the area under the population analysis profile-time curve.
The use of a relatively low starting inoculum-10 7 to 10 8 CFU (7, 18)-with few if any resistant mutants also might result in uncertain findings, because these inocula may contain only one resistant cell (35) . It is not by chance that resistance data obtained in a study with moxifloxacin-and levofloxacinexposed S. aureus at a starting inoculum of 10 6 CFU/ml in a 60-ml volume (6 ϫ 10 7 CFU) (14) were less reproducible than those in the present study, where the starting inoculum was 6 ϫ 10 9 CFU. Pharmacodynamics. As in a previous pharmacodynamic study of moxifloxacin and levofloxacin against a less-susceptible strain of S. aureus at a lower starting inoculum (14) , a specific AUC 24 /MIC relationship with I E was inherent for each of the four quinolones studied. This resulted in different antimicrobial effects of the quinolones at a given AUC 24 /MIC ratio. These differences were primarily seen at the high simulated AUC 24 /MIC ratios, whereas at lower AUC /MIC ratios, no differences were detected among the curves. Similar patterns of the I E -versus-log AUC/MIC relationships were reported in a previous single-dose study with gemifloxacin and ciprofloxacin against S. aureus (12) .
Overall, the data obtained in this study are consistent with the concept that resistant mutants are selectively enriched when antibiotic concentrations fall inside the MSW. They also suggest that in vitro dynamic models can be used to predict the relative abilities of fluoroquinolones to prevent mutant selection, although further studies with other organisms are needed. 
